glp·helper
glphelper.com/ozempic/illinois/crystal-lake
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Crystal Lake, IL

Verified Ozempic providers in Crystal Lake, IL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
28
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Illinois
28 of 28 shown

Find an Ozempic provider in Illinois.

Every entry is checked against the NPI registry and the Illinois medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Illinois city · /ozempic/illinois/{city}
§ 03Getting Ozempic in Crystal Lake
28 providers · Crystal Lake, IL

How to get Ozempic in Crystal Lake.

28 GLP-1 prescribers and 7 local resource types are on record for Crystal Lake, plus 3 nearby towns in the directory.

Prescribers in Crystal Lake
28 prescribers
28 GLP-1 prescribers in Crystal Lake, most listed as Family Medicine (12), Internal Medicine (8) and Internal Medicine, Endocrinology, Diabetes & Metabolism (6). Any Illinois-licensed physician, nurse practitioner, or PA can prescribe Ozempic, over video or in person. The nearest towns on record are Elgin (21 providers), Palatine (27 providers) and Schaumburg (24 providers).
Around the prescription in Crystal Lake
7 listed nearby
27 dietitians, 3 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Crystal Lake.
Medicaid (weight loss)
Diabetes only
As of April 2026, Illinois Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Illinois’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Crystal Lake

Crystal Lake, Illinois has a population of 40,269 people. The adult obesity rate in Crystal Lake is an age-adjusted estimate of 31.4%, 2.8 percentage points below the Illinois state rate of 34.2%. Diagnosed diabetes reaches 8.5% of adults in Crystal Lake. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 19.4% of adults in Crystal Lake.

of Crystal Lake adults have obesity
31.4%
diagnosed diabetes
8.5%
no regular physical activity
19.4%

Age-adjusted estimates for Crystal Lake, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossOzempic babies explained
§ 05Support around Ozempic in Crystal Lake
6 dietitians

The prescription is one part. Here is the rest, in Crystal Lake.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Crystal Lake, IL, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Lora Anderson, RD CSO LDN
RD
Registered dietitian · Oncology
4305 W Medical Center Dr
Call 815-344-8000NPI 1982285672
Emily Bixler, RDN
RD
Registered dietitian
110 W Woodstock St Ste A
Call 262-210-2819NPI 1821616517
Anne Borris, RD LDN
RD
Registered dietitian
10350 Haligus Rd Ste 220
Call 815-338-6600NPI 1316364367
Dolores Budelier, RD, LDN, CDE
RD
Registered dietitian
4201 W Medical Center Dr
Call 815-759-4103NPI 1861548257
Sarah Buytendorp, RD
RD
Registered dietitian
10450 Algonquin Rd Ste 100A
Call 815-334-5566NPI 1770713984
Jinger Christal, RD
RD
Registered dietitian
10450 Algonquin Rd Ste 100A
Call 815-334-5566NPI 1710605944

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Tessa Blumthal
NUTRITIONIST
Nutritionist
390 E Congress Pkwy Ste J
Call 815-322-9300NPI 1952238784
Erika Dycus, RN LDN
NUTRITIONIST
Nutritionist
2387 Achilles Ct
Call 815-451-9367NPI 1467147140
Erica Gazija
NUTRITIONIST
Nutritionist
390 E Congress Pkwy Ste J
Call 815-322-9300NPI 1326907858
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in Illinois

NPI-verified Ozempic (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Illinois

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]